Johannes Schetelig On Remission Induction Versus Immediate Allogeneic HSCT For Patients With AML The Lancet Haematology In Conversation With podcast

Content provided by The Lancet Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Lancet Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

The Lancet Haematology in conversation with »
Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML

8h ago 14:11

MP3•Episode home

Professor Johannes Schetelig joins us to discuss the results of the ASAP phase 3 trial comparing remission induction with immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia.
Read the full article:
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00065-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

45 episodes

#Science #Biology #Fitness #Medicine #Podcasting Education #The Lancet Group #Blood #Haemophilia #Haematology #Leukaemia

Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML

The Lancet Haematology in conversation with

published 8h ago

MP3•Episode home

45 episodes

#Science #Biology #Fitness #Medicine #Podcasting Education #The Lancet Group #Blood #Haemophilia #Haematology #Leukaemia

All episodes

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.